ClinicalTrials.gg
CompletedNCT06572449Updated Jun 22, 2026Results posted

Study to Assess Safety and Effectiveness of Slowly Increasing Dose and Food Effect of KarXT in Participants With Schizophrenia

A Phase 3 interventional study of KarXT in Schizophrenia, sponsored by Karuna Therapeutics, Inc., a Bristol Myers Squibb company. Completed at 6 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-06-22.

Sponsored by Karuna Therapeutics, Inc., a Bristol Myers Squibb company (part of Bristol-Myers Squibb) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
173
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies testing xanomeline in Schizophrenia — 9 open to participants now, 9 under way, 4 of them phase 3. xanomeline · Schizophrenia.

Enrollment
11th of 20
173 · median 178
Started
2024
the only one that year
Phase 3
14 of 20
4 open now
Registered
10th of 20
by date
Lead sponsor
7 of 20
Karuna Therapeutics, Inc., a Bristol Myers Squibb company

Among the 20 studies testing xanomeline in Schizophrenia, this one is the 11th largest by enrollment, is the only one that started in 2024, is one of 14 in phase 3, and was the 10th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

9 of the 20 studies testing xanomeline in Schizophrenia are open now, in 12 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About xanomeline

xanomeline: first FDA approval 2024 (COBENFY). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing xanomeline in Schizophrenia, or all of them as a file.
02

Study summary

The purpose of this study is to assess the safety and efficacy of slowly increasing dose and food effect of KarXT in adult participants with schizophrenia.

03

Conditions studied

  • Schizophrenia

Keywords

  • BMS-986510
  • KarXT
  • DSM-5 Schizophrenia
  • Diagnostic and Statistical Manual of Mental Disorders
  • Mental Disorders
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has a primary diagnosis of schizophrenia established by a comprehensive psychiatric evaluation based on the (American Psychiatric Association 2013) criteria and confirmed by Mini International Neuropsychiatric Interview (MINI) for Schizophrenia and Psychotic Disorder Studies version 7.0.2.
  • Positive and Negative Syndrome Scale (PANSS) total score of ≤ 80 at screening and Baseline.
  • Clinical Global Impression-Severity (CGI-S) score of ≤ 4 at screening and Baseline.
  • Willing and able to discontinue all antipsychotic medications prior to baseline visit.

Exclusion criteria

Exclusion Criteria:

  • History or presence of cardiovascular, pulmonary, renal, hematologic, gastrointestinal (GI), endocrine, immunologic, dermatologic, neurologic, or oncologic disease or any other condition that, in the opinion of the investigator, would jeopardize the safety of the participant or the validity of the study results.
  • Any primary disorder other than schizophrenia within 12 months before screening.
  • History of treatment resistance to schizophrenia medications.
  • History of allergy/ to KarXT.
  • Other protocol-defined Inclusion/Exclusion criteria apply.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
173 participants (actual)

Study arms

  • Experimental
    KarXT on empty stomach and with food

    Drug: KarXT

Interventions

  • DrugKarXT

    Drug pages: Xanomeline · Trospium

    Specified dose on specified days

    Also known as: BMS-986510

06

What researchers measure

Primary outcomes

  1. Number of Participants With TEAEs From First Dose to End of Study Follow up.

    Number of participants with Treatment Emergent Adverse Events (TEAEs) from first dose to end of study follow up. An adverse event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition occurring in a clinical investigation participant after signing of informed consent, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (such as an abnormal laboratory test result), symptom, or disease temporally associated with the study intervention.

    Time frame: From first dose to end of study follow up (63 days)

  2. Number of Participants With TEAEs at the End of Period 1 and Period 2.

    Number of participants with TEAEs at the end of period 1 and period 2. An adverse event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition occurring in a clinical investigation participant after signing of informed consent, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (such as an abnormal laboratory test result), symptom, or disease temporally associated with the study intervention.

    Time frame: Period 1 (From first dose to day 28) Period 2 (day 29 to day 56)

  3. Number of Participants With Serious TEAEs at the End of Period 1 and Period 2.

    Number of participants with TEAEs at the end of period 1 and period 2. Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, and requires inpatient hospitalization or causes prolongation of existing hospitalization.

    Time frame: Period 1 (From first dose to day 28); Period 2 (day 29 to day 56); Overall (63 days)

  4. Number of Participants With TEAEs Leading to Treatment Discontinuation.

    Number of participants with TEAEs leading to treatment discontinuation.

    Time frame: Period 1 (From first dose to day 28); Period 2 (day 29 to day 56); Overall (63 days)

  5. Number of Participants With Pro-cholinergic and Anticholinergic TEAEs.

    The number of participants experiencing adverse events related to procholinergic symptoms (believed to be associated with xanomeline) and anticholinergic symptoms (believed to be associated with trospium) symptoms. Examples of procholinergic symptoms include vomiting, nausea, diarrhea, sweating and hyper-salivation. Examples of anticholinergic include dizziness, confusion, hallucinations, and somnolence.

    Time frame: Period 1 (From first dose to day 28); Period 2 (day 29 to day 56); Overall (63 days)

Secondary outcomes

  1. Change From Baseline in PANSS Total Score, Positive Score and Negative Score

    The Positive and Negative Syndrome Scale (PANSS) assesses schizophrenia symptom severity using 30 items: 7 positive, 7 negative, and 16 general psychopathology scales. Each item is rated from 1 (absent) to 7 (extreme). Positive symptoms represent excesses or distortions of normal function (e.g., hallucinations, delusions), while negative symptoms reflect diminished function. The PANSS positive and negative scores each sum their respective 7 items, ranging from 7 to 49, with higher scores indicating greater severity. The PANSS Total Score sums all 30 items, ranging from 30 to 210, with higher scores reflecting worse overall symptom severity.

    Time frame: From first dose to end of treatment (56 days)

  2. Change From Baseline in Marder Factor Score.

    PANSS Marder factor score is the sum of 5 negative scales and 2 general scales (N1. Blunted affect; N2. Emotional withdrawal; N3. Poor rapport; N4. Passive/apathetic social withdrawal; N6. Lack of spontaneity; G7. Motor retardation; and G16. Active social avoidance). Participants are rated from 1 to 7 on each symptom scale, with a total score ranging from 7 to 49. Higher score indicates more severe symptoms. The negative symptoms in schizophrenia are the diminution or loss of normal functions. Baseline is defined as the PANSS score at screening.

    Time frame: From first dose to end of treatment (56 days)

  3. Change From Baseline in CGI Severity Score

    Completed independently by a clinician, the CGI-S categorizes the severity of the illness as: 1 = Normal, not at all ill; 2 = Borderline mentally ill; 3 = Mildly ill; 4 = Moderately ill; 5 = Markedly ill; 6 = Severely ill; and 7 = Among the most extremely ill patients, by asking the clinical 1 question and providing a rating based upon observed and reported symptoms, behavior, and function in the past 7 days to reflect the average severity level across the 7 days. Higher score indicates more severe illness.

    Time frame: From first dose to end of treatment (56 days)

  4. Number of Participants With Spontaneously Reported AESIs

    The AEs of special interest (AESIs) will be monitored and include symptomatic orthostasis, syncope(a transient loss of consciousness or fainting),and liver function test elevations as defined below. For SAE reporting requirements for events of liver injury.

    Time frame: From first dose to end of study follow up (63 days)

  5. Number of Participants With Clinically Significant Changes in Vital Signs

    Number of participants with clinically significant changes in vital signs

    Time frame: From first dose to end of study follow up (63 days)

  6. Number of Participants With Clinically Significant Changes in Clinical Laboratory Assessments

    Number of participants with clinically significant changes in clinical laboratory assessments

    Time frame: From first dose to end of study follow up (63 days)

  7. Number of Participants With Clinically Significant Changes in 12-lead ECGs

    Number of participants with clinically significant changes in 12-lead ECGs

    Time frame: From first dose to end of study follow up (63 days)

  8. Number of Participants Who Exhibited Suicidal Behavior as Assessed by C-SSRS

    Number of participants who exhibited suicidal behavior as assessed by C-SSRS

    Time frame: From first dose to end of study follow up (63 days)

07

Results

Posted Jun 22, 2026

Participant flow

Treatment Period
Participant flow — Treatment Period
MilestoneCohort 1Cohort 2
Started10073
Completed8356
Not completed1717
Withdrew: Requested to discontinue study treatment1411
Withdrew: Adverse event16
Withdrew: Other reasons10
Withdrew: No longer meets study critieria10
Follow Up
Participant flow — Follow Up
MilestoneCohort 1Cohort 2
Started10073
Completed8353
Not completed1720
Withdrew: Withdrawal of consent by participant1316
Withdrew: Lost to follow-up23
Withdrew: Other reasons11
Withdrew: No longer meets study criteria10

Outcome measures

SecondaryChange From Baseline in PANSS Total Score, Positive Score and Negative Score

The Positive and Negative Syndrome Scale (PANSS) assesses schizophrenia symptom severity using 30 items: 7 positive, 7 negative, and 16 general psychopathology scales. Each item is rated from 1 (absent) to 7 (extreme). Positive symptoms represent excesses or distortions of normal function (e.g., hallucinations, delusions), while negative symptoms reflect diminished function. The PANSS positive and negative scores each sum their respective 7 items, ranging from 7 to 49, with higher scores indicating greater severity. The PANSS Total Score sums all 30 items, ranging from 30 to 210, with higher scores reflecting worse overall symptom severity.

Time frame:
From first dose to end of treatment (56 days)
Reported as:
Mean · Score on a Scale
Change From Baseline in PANSS Total Score, Positive Score and Negative Score
Score on a ScaleCohort 1Cohort 2
Total Score-3.9 ± 8.98-2.7 ± 7.40
Positive Score-1.7 ± 3.37-0.9 ± 2.40
Negative Score-0.7 ± 3.15-0.9 ± 2.34
SecondaryChange From Baseline in Marder Factor Score.

PANSS Marder factor score is the sum of 5 negative scales and 2 general scales (N1. Blunted affect; N2. Emotional withdrawal; N3. Poor rapport; N4. Passive/apathetic social withdrawal; N6. Lack of spontaneity; G7. Motor retardation; and G16. Active social avoidance). Participants are rated from 1 to 7 on each symptom scale, with a total score ranging from 7 to 49. Higher score indicates more severe symptoms. The negative symptoms in schizophrenia are the diminution or loss of normal functions. Baseline is defined as the PANSS score at screening.

Time frame:
From first dose to end of treatment (56 days)
Reported as:
Mean · Score on a Scale
Change From Baseline in Marder Factor Score.
Score on a ScaleCohort 1Cohort 2
Change From Baseline in Marder Factor Score.-1.2 ± 3.0714.5 ± 3.76
SecondaryChange From Baseline in CGI Severity Score

Completed independently by a clinician, the CGI-S categorizes the severity of the illness as: 1 = Normal, not at all ill; 2 = Borderline mentally ill; 3 = Mildly ill; 4 = Moderately ill; 5 = Markedly ill; 6 = Severely ill; and 7 = Among the most extremely ill patients, by asking the clinical 1 question and providing a rating based upon observed and reported symptoms, behavior, and function in the past 7 days to reflect the average severity level across the 7 days. Higher score indicates more severe illness.

Time frame:
From first dose to end of treatment (56 days)
Reported as:
Mean · Score on a Scale
Change From Baseline in CGI Severity Score
Score on a ScaleCohort 1Cohort 2
Change From Baseline in CGI Severity Score-0.2 ± 0.66-0.1 ± 0.50
SecondaryNumber of Participants With Spontaneously Reported AESIs

The AEs of special interest (AESIs) will be monitored and include symptomatic orthostasis, syncope(a transient loss of consciousness or fainting),and liver function test elevations as defined below. For SAE reporting requirements for events of liver injury.

Time frame:
From first dose to end of study follow up (63 days)
Reported as:
Count of participants · Participants
Number of Participants With Spontaneously Reported AESIs
ParticipantsCohort 1Cohort 2
Number of Participants With Spontaneously Reported AESIs21
SecondaryNumber of Participants With Clinically Significant Changes in Vital Signs

Number of participants with clinically significant changes in vital signs

Time frame:
From first dose to end of study follow up (63 days)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Changes in Vital Signs
ParticipantsCohort 1Cohort 2
Number of Participants With Clinically Significant Changes in Vital Signs00
SecondaryNumber of Participants With Clinically Significant Changes in Clinical Laboratory Assessments

Number of participants with clinically significant changes in clinical laboratory assessments

Time frame:
From first dose to end of study follow up (63 days)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Changes in Clinical Laboratory Assessments
ParticipantsCohort 1Cohort 2
Number of Participants With Clinically Significant Changes in Clinical Laboratory Assessments00
SecondaryNumber of Participants With Clinically Significant Changes in 12-lead ECGs

Number of participants with clinically significant changes in 12-lead ECGs

Time frame:
From first dose to end of study follow up (63 days)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Changes in 12-lead ECGs
ParticipantsCohort 1Cohort 2
Number of Participants With Clinically Significant Changes in 12-lead ECGs00
SecondaryNumber of Participants Who Exhibited Suicidal Behavior as Assessed by C-SSRS

Number of participants who exhibited suicidal behavior as assessed by C-SSRS

Time frame:
From first dose to end of study follow up (63 days)
Reported as:
Count of participants · Participants
Number of Participants Who Exhibited Suicidal Behavior as Assessed by C-SSRS
ParticipantsCohort 1Cohort 2
Number of Participants Who Exhibited Suicidal Behavior as Assessed by C-SSRS00
PrimaryNumber of Participants With TEAEs From First Dose to End of Study Follow up.

Number of participants with Treatment Emergent Adverse Events (TEAEs) from first dose to end of study follow up. An adverse event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition occurring in a clinical investigation participant after signing of informed consent, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (such as an abnormal laboratory test result), symptom, or disease temporally associated with the study intervention.

Time frame:
From first dose to end of study follow up (63 days)
Reported as:
Count of participants · Participants
Number of Participants With TEAEs From First Dose to End of Study Follow up.
ParticipantsCohort 1Cohort 2
TEAE7255
Treatment Related TEAEs6144
PrimaryNumber of Participants With TEAEs at the End of Period 1 and Period 2.

Number of participants with TEAEs at the end of period 1 and period 2. An adverse event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition occurring in a clinical investigation participant after signing of informed consent, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (such as an abnormal laboratory test result), symptom, or disease temporally associated with the study intervention.

Time frame:
Period 1 (From first dose to day 28) Period 2 (day 29 to day 56)
Reported as:
Count of participants · Participants
Number of Participants With TEAEs at the End of Period 1 and Period 2.
ParticipantsCohort 1Cohort 2
Period 1 (First dose to day 28)6249
Period 2 (from day 29 to day 56)3426
PrimaryNumber of Participants With Serious TEAEs at the End of Period 1 and Period 2.

Number of participants with TEAEs at the end of period 1 and period 2. Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, and requires inpatient hospitalization or causes prolongation of existing hospitalization.

Time frame:
Period 1 (From first dose to day 28); Period 2 (day 29 to day 56); Overall (63 days)
Reported as:
Count of participants · Participants
Number of Participants With Serious TEAEs at the End of Period 1 and Period 2.
ParticipantsCohort 1Cohort 2
Period 1 (First dose to day 28)00
Period 2 (from day 29 to day 56)00
From First dose to day 6300
PrimaryNumber of Participants With TEAEs Leading to Treatment Discontinuation.

Number of participants with TEAEs leading to treatment discontinuation.

Time frame:
Period 1 (From first dose to day 28); Period 2 (day 29 to day 56); Overall (63 days)
Reported as:
Count of participants · Participants
Number of Participants With TEAEs Leading to Treatment Discontinuation.
ParticipantsCohort 1Cohort 2
Period 1 (First dose to day 28)12
Period 2 (from day 29 to day 56)03
From First dose to day 6315
PrimaryNumber of Participants With Pro-cholinergic and Anticholinergic TEAEs.

The number of participants experiencing adverse events related to procholinergic symptoms (believed to be associated with xanomeline) and anticholinergic symptoms (believed to be associated with trospium) symptoms. Examples of procholinergic symptoms include vomiting, nausea, diarrhea, sweating and hyper-salivation. Examples of anticholinergic include dizziness, confusion, hallucinations, and somnolence.

Time frame:
Period 1 (From first dose to day 28); Period 2 (day 29 to day 56); Overall (63 days)
Reported as:
Count of participants · Participants
Number of Participants With Pro-cholinergic and Anticholinergic TEAEs.
ParticipantsCohort 1Cohort 2
Period 1 Procholinergic3121
Period 1 Anticholinergic3427
Period 2 Procholinergic136
Period 2 Anticholinergic95
Overall Procholinergic3826
Overall Anticholinergic4130

Adverse events

Collected over All AEs and SAEs are collected on or after the first dosing date through the end of the safety follow up (Day 63 ± 3 days) or EOT+7 (Day 56+7 ±3 days). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 10/100 (0%)0/100 (0%)54/100 (54%)
Cohort 20/73 (0%)0/73 (0%)44/73 (60.3%)
Most frequent other events
Showing 10 of 11
Most frequent other events
EventCohort 1Cohort 2
NauseaGastrointestinal disorders30/10017/73
DyspepsiaGastrointestinal disorders19/10016/73
HeadacheNervous system disorders13/10016/73
VomitingGastrointestinal disorders17/10013/73
ConstipationGastrointestinal disorders13/10012/73
Gastrooesophageal reflux diseaseGastrointestinal disorders7/1008/73
Abdominal discomfortGastrointestinal disorders7/1002/73
DizzinessNervous system disorders7/1005/73
PruritusSkin and subcutaneous tissue disorders2/1005/73
Dry mouthGastrointestinal disorders6/1002/73

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Cohort 1Cohort 2Total
<=18 years000
Between 18 and 65 years10073173
>=65 years000
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1Cohort 2Total
Female272047
Male7353126
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cohort 1Cohort 2Total
Hispanic or Latino181432
Not Hispanic or Latino8257139
Unknown or Not Reported022
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohort 1Cohort 2Total
American Indian or Alaska Native000
Asian101
Native Hawaiian or Other Pacific Islander000
Black or African American7553128
White231942
More than one race000
Unknown or Not Reported112
08

Study locations

6 sites
  • Local Institution - 0002
    Los Alamitos, California 90720-3118, United States
  • Local Institution - 0004
    Riverside, California 92506-3257, United States
  • Local Institution - 0006
    Hollywood, Florida 33024, United States
  • Local Institution - 0005
    Atlanta, Georgia 30331, United States
  • Local Institution - 0003
    Decatur, Georgia 30030, United States
  • Local Institution - 0001
    Marlton, New Jersey 08053-3449, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at: https://www.bms.com/researchers-and-partners/clinical-trials-and-research/disclosurecommitment.html

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See Plan Description

Access criteria: See Plan Description

Data sharing details ↗ · www.bms.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2024 to primary completion in Mar 2025, 4 months.

Results were first posted in Jun 2026, 1 year 3 months after primary completion.

Of 99 industry-sponsored phase 3 interventional studies under Schizophrenia, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 41. This study's 4 months is below that.

Counting every sponsor, half of 113 studies reached it within 32 months; a quarter within 20 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 8, 2024
First posted
Aug 27, 2024
StartActual
Oct 28, 2024
Primary completionActual
Mar 13, 2025
CompletionActual
Mar 13, 2025
Results first posted
Jun 22, 2026
Last update
Jun 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06572449
Responsible party
Sponsor
First posted
Aug 27, 2024
Start date
Oct 28, 2024
Primary completion
Mar 13, 2025
Completion
Mar 13, 2025
Results posted
Jun 22, 2026
Last update
Jun 22, 2026

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Xanomeline · Trospium

Start the discussion